Serum uric acid and cardiovascular risk: State of the art and perspectives

Joint Bone Spine

Volumn 81, Issue 5, 2014, Pages 392-397

  Fenech, Goël ^a   Rajzbaum, Gérald ^b   Mazighi, Mikaël ^c   Blacher, Jacques ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Fondation Institution Saint Joseph   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Cardiovascular diseases; Cardiovascular risk factor; Confounding factors; Reversibility; Serum uric acid

Indexed keywords

URIC ACID;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; DIABETES MELLITUS; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; URIC ACID BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; HYPERURICEMIA; RISK FACTORS; URIC ACID;

EID: 84927696929     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.01.008     Document Type: Short Survey

References (70)

1. Burns C.M., Wortmann R.L. Gout therapeutics: new drugs for an old disease. Lancet 2011, 377:165-177.
2. Wallace S.L., Robinson H., Masi A.T., et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
3. Richette P., Bardin T. Gout. Lancet 2010, 375:318-328.
4. Vitart V., Rudan I., Hayward C., et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008, 40:437-442.
5. Krishnan E., Lessov-Schlaggar C.N., Krasnow R.E., et al. Nature versus nurture in gout: a twin study. Am J Med 2012, 125:499-504.
6. Zhang W., Doherty M., Pascual E., et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1301-1311.
7. Lawrence R.C., Felson D.T., Helmick C.G., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35.
8. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63:3136-3141.
9. Roddy E., Doherty M. Epidemiology of gout. Arthritis Res Ther 2010, 12:223.
10. Cea Soriano L., Rothenbacher D., Choi H.K., et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011, 13:R39.
11. Trifiro G., Morabito P., Cavagna L., et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 2013, 72:694-700.
12. Grassi D., Ferri L., Desideri G., et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des 2013, 19:2432-2438.
13. Crouse J.R., Toole J.F., McKinney W.M., et al. Risk factors for extracranial carotid artery atherosclerosis. Stroke 1987, 18:990-996.
14. Nieto F.J., Iribarren C., Gross M.D., et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
15. Tuttle K.R., Short R.A., Johnson R.J. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001 Jun 15, 87:1411-1414.
16. Iribarren C., Folsom A.R., Eckfeldt J.H., et al. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis risk in communities. Ann Epidemiol 1996, 6:331-340.
17. Mutluay R., Deger S.M., Bahadir E., et al. Uric acid is an important predictor for hypertensive early atherosclerosis. Adv Ther 2012, 29:276-286.
18. Kanellis J., Watanabe S., Li J.H., et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41:1287-1293.
19. Kang D.H., Park S.K., Lee I.K., et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16:3553-3562.
20. Corry D.B., Eslami P., Yamamoto K., et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008, 26:269-275.
21. Suarna C., Dean R.T., May J., et al. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 1995, 15:1616-1624.
22. Ginsberg M.H., Kozin F., O'Malley M., et al. Release of platelet constituents by monosodium urate crystals. J Clin Invest 1977, 60:999-1007.
23. Fuster V., Badimon L., Badimon J.J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992, 326:310-318.
24. George J., Struthers A.D. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Ther 2008, 26:59-64.
25. George J., Carr E., Davies J., et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006, 114:2508-2516.
26. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811-1821.
27. Grayson P.C., Kim S.Y., LaValley M., et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011, 63:102-110.
28. Shah A., Keenan R.T. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?. Curr Rheumatol Rep 2010, 12:118-124.
29. Mellen P.B., Bleyer A.J., Erlinger T.P., et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006, 48:1037-1042.
30. Kahn H.A., Medalie J.H., Neufeld H.N., et al. The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J 1972, 84:171-182.
31. Selby J.V., Friedman G.D., Quesenberry C.P. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990, 131:1017-1027.
32. Hunt S.C., Stephenson S.H., Hopkins P.N., et al. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991, 17:969-976.
33. Jossa F., Farinaro E., Panico S., et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994, 8:677-681.
34. Taniguchi Y., Hayashi T., Tsumura K., et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens 2001, 19:1209-1215.
35. Masuo K., Kawaguchi H., Mikami H., et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003, 42:474-480.
36. Nakanishi N., Okamoto M., Yoshida H., et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003, 18:523-530.
37. Alper A.B., Chen W., Yau L., et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005, 45:34-38.
38. Sundstrom J., Sullivan L., D'Agostino R.B., et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005, 45:28-33.
39. Johnson R.J., Feig D.I., Herrera-Acosta J., et al. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005, 45:18-20.
40. Mazzali M., Hughes J., Kim Y.G., et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106.
41. Mazzali M., Kanellis J., Han L., et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282:F991-F997.
42. Perlstein T.S., Gumieniak O., Hopkins P.N., et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004, 66:1465-1470.
43. Quinones Galvan A., Natali A., Baldi S., et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995, 268:E1-E5.
44. Messerli F.H., Frohlich E.D., Dreslinski G.R., et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980, 93:817-821.
45. Palmer T.M., Nordestgaard B.G., Benn M., et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 2013, 347:f4262.
46. Sui X., Church T.S., Meriwether R.A., et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008, 57:845-852.
47. Ioachimescu A.G., Brennan D.M., Hoar B.M., et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008, 58:623-630.
48. Freedman D.S., Williamson D.F., Gunter E.W., et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995, 141:637-644.
49. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283:2404-2410.
50. Bos M.J., Koudstaal P.J., Hofman A., et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006, 37:1503-1507.
51. Kuo C.F., See L.C., Yu K.H., et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013, 52:127-134.
52. Wheeler J.G., Juzwishin K.D., Eiriksdottir G., et al. Serum uric acid and coronary heart disease in 9458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005, 2:e76.
53. Culleton B.F., Larson M.G., Kannel W.B., et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131:7-13.
54. Alderman M.H. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002, 2:126-130.
55. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991, 59:364-368.
56. Verdecchia P., Schillaci G., Reboldi G., et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000, 36:1072-1078.
57. Alderman M.H., Cohen H., Madhavan S., et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999, 34:144-150.
58. Lehto S., Niskanen L., Ronnemaa T., et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998, 29:635-639.
59. Krishnan E., Pandya B.J., Lingala B., et al. Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther 2012, 14:R10.
60. Chamorro A., Obach V., Cervera A., et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002, 33:1048-1052.
61. Yu Z.F., Bruce-Keller A.J., Goodman Y., et al. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998, 53:613-625.
62. Weir C.J., Muir S.W., Walters M.R., et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003, 34:1951-1956.
63. Farrell B., Godwin J., Richards S., et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044-1054.
64. Clark T.G., Murphy M.F., Rothwell P.M. Long term risks of stroke, myocardial infarction, and vascular death in "low risk" patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry 2003, 74:577-580.
65. Koton S., Howard S.C., Warlow C.P., et al. Serum urate predicts long-term risk of acute coronary events in women after a transient ischaemic attack and stroke. Cerebrovasc Dis 2008, 26:517-524.
66. Hoieggen A., Alderman M.H., Kjeldsen S.E., et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 65:1041-1049.
67. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 1965, 58:295-300.
68. Dobson A. Is raised serum uric acid a cause of cardiovascular disease or death?. Lancet 1999, 354:1578.
69. Feig D.I., Soletsky B., Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924-932.
70. Luk A.J., Levin G.P., Moore E.E., et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 2009, 48:804-806.